Search is Powered by Google
Cancer / Oncology News

Why Chemo Works For Some People And Not Others - MIT Cell Findings Could Predict Individuals' Responses

Main Category: Cancer / Oncology
Also Included In: Genetics;  Biology / Biochemistry
Article Date: 20 Sep 2008 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:5 stars

5 (2 votes)

Health Professional:not yet rated

Article Opinions: 1 posts

MIT researchers have shown that cells from different people don't all react the same way when exposed to the same DNA-damaging agent - a finding that could help clinicians predict how patients will respond to chemotherapy.

The research team from MIT's Center for Environmental Health Sciences (CEHS) and the Departments of Biological Engineering and Biology, identified a group of 48 genes that can predict how susceptible an individual is to the toxic compound, known as MNNG. The work appears in the Sept. 19 online edition of Genes and Development.

MNNG, a DNA-damaging compound similar to toxic chemicals found in tobacco smoke and in common chemotherapy agents, usually kills cells by inducing irreparable DNA damage. However, the researchers found a wide range of susceptibility among cells taken from healthy people.

"A cell line from one person would be killed dramatically, while that from another person was resistant to exposure," said Rebecca Fry, former MIT research scientist and lead author of the paper. "It wasn't known that cell lines from different people could have such dramatic differences in responses."

Toxic agents such as MNNG create lesions in DNA, provoking the cell to defend itself with a variety of DNA-repair and other pathways. However, every individual expresses slight differences in the genes involved in those pathways.

"Even if everyone is exposed to exactly the same things, they would respond differently, because we're all genetically different," said Leona Samson, senior author of the paper, director of CEHS, and an American Cancer Society Research Professor.

The team members found that after measuring the expression of every gene in each cell line, they could predict cell sensitivity to MNNG from the expression of just 48 specific genes, with 94 percent accuracy.

Several of those 48 genes have already been linked to cancer, said Samson, but it was not known that their expression is already altered before exposure to the DNA damaging agent.

This study is specific to MNNG, but similar efforts are now underway in Samson's lab to predict individuals' responses to other toxic agents, including cisplatin, a common chemotherapy agent, and temozolomide, used to treat brain cancer.

Fry, the lead author of the paper, is now an assistant professor at the University of North Carolina School of Public Health. Other authors are Peter Svensson, a postdoctoral fellow in CEHS; Chandni Valiathan, a graduate student in computational and systems biology; Emma Wang and Brad Hogan, technical assistants in CEHS; Sanchita Bhattacharya, former CEHS research scientist; James Bugni, former CEHS postdoctoral fellow; and Charles Whittaker, a research scientist in the David H. Koch Institute for Integrative Cancer Research.

The research was funded by the National Institute of Environmental Health Sciences and the National Cancer Institute.

By Anne Trafton, MIT News Office

Massachusetts Institute of Technology




Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Urology
ADHD Autism Diabetes

add medical news today to your facebook

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


customize your homepage


These are the most read articles from this news category for the last 6 months:
Top Article Star
Shocking Pictures To Appear On Cigarette Packets In UK On 1st October
27 Sep 2008
The UK's ten million Smokers may see pictures of rotting teeth, throat cancer, and indications of male impotence (erectile dysfunction) on cigarette packets they buy at the beginning of October...


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...